U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C28H39NO5
Molecular Weight 469.613
Optical Activity UNSPECIFIED
Defined Stereocenters 3 / 3
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of ARTEFENOMEL

SMILES

C(CN1CCOCC1)OC2=CC=C(C=C2)[C@H]3CC[C@@]4(CC3)OO[C@@]5(O4)C6CC7CC(C6)CC5C7

InChI

InChIKey=XLCNVWUKICLURR-WMORPJFDSA-N
InChI=1S/C28H39NO5/c1-3-26(31-14-11-29-9-12-30-13-10-29)4-2-22(1)23-5-7-27(8-6-23)32-28(34-33-27)24-16-20-15-21(18-24)19-25(28)17-20/h1-4,20-21,23-25H,5-19H2/t20?,21?,23-,24?,25?,27-,28-

HIDE SMILES / InChI

Description

Artefenomel, a novel trioxolane, is a lead candidate for inclusion in a new antimalarial combination, specifically formulated for children. Artefenomel has been demonstrated curative in as little as one dose.

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
Unknown

Cmax

ValueDoseCo-administeredAnalytePopulation
1710 ng/mL
800 mg single, oral
ARTEFENOMEL plasma
Homo sapiens
1500 ng/mL
1200 mg single, oral
ARTEFENOMEL plasma
Homo sapiens
339 ng/mL
200 mg single, oral
ARTEFENOMEL plasma
Homo sapiens
732 ng/mL
400 mg single, oral
ARTEFENOMEL plasma
Homo sapiens

AUC

ValueDoseCo-administeredAnalytePopulation
19700 ng × h/mL
800 mg single, oral
ARTEFENOMEL plasma
Homo sapiens
25100 ng × h/mL
1200 mg single, oral
ARTEFENOMEL plasma
Homo sapiens
3180 ng × h/mL
200 mg single, oral
ARTEFENOMEL plasma
Homo sapiens
6450 ng × h/mL
400 mg single, oral
ARTEFENOMEL plasma
Homo sapiens

T1/2

ValueDoseCo-administeredAnalytePopulation
58 h
800 mg single, oral
ARTEFENOMEL plasma
Homo sapiens
57 h
1200 mg single, oral
ARTEFENOMEL plasma
Homo sapiens
46.3 h
200 mg single, oral
ARTEFENOMEL plasma
Homo sapiens
62.3 h
400 mg single, oral
ARTEFENOMEL plasma
Homo sapiens

Overview

OverviewOther

Other InhibitorOther SubstrateOther Inducer





Drug as perpetrator​

Drug as victim

PubMed

Sample Use Guides

In Vivo Use Guide
In clinical trials, Artefenomel is administered in 800 mg doses in loose combination with Piperaquine phosphate doses of either 640, 960, 1440 mg
Route of Administration: Oral
In Vitro Use Guide
Asexual parasites were seeded at a density of 0.5% parasitemia in 3% hematocrit in a black 384-well plate in 30 μL of culture medium, and 30 μL of diluted compound was added. Following a 72 h incubation at 37°C, 98% humidity, 93% N2, 4% CO2 and 3% O2, the increase in parasitemia was assessed using the modified Plasmodium lactate dehydrogenase assay. Artefenomel was diluted in DMSO and subsequently in culture medium to reach a final DMSO concentration of 0.1%.